Aims Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely
manner according to evidence‐based clinical guidelines, is a key reason for uncontrolled …

Poor glycaemic control in type 2 diabetes (T2D) is a global problem despite the availability
of numerous glucose‐lowering therapies and clear guidelines for T2D management …

Background Insulin icodec (icodec) is a once-weekly basal insulin currently under
development. ONWARDS 2 aimed to assess the efficacy and safety of once-weekly icodec …

OBJECTIVE Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial
investigated two approaches for switching to icodec versus once-daily insulin glargine 100 …

Purpose Clinical inertia and medication non-adherence are thought to contribute largely to
the suboptimal glycemic control in many patients with type 2 diabetes. The present review …

Aims To determine the patterns and predictors of treatment intensification in patients with
type 2 diabetes on≥ 2 non‐insulin antidiabetic drugs (NIAD s) and inadequate glycaemic …

Throughout history, up to the early part of the 20th century, diabetes has been a devastating
disorder, particularly when diagnosed in childhood when it was usually fatal. Consequently …

Background Therapeutic inertia leading to delays in insulin initiation or intensification is a
major contributor to lack of optimal diabetes care. This report reviews the literature …

Aims: This study aimed to explore barriers regarding insulin initiation in patients with Type 2
diabetes and investigate the relationship of some demographic characters of patients …

Introducción: Poco se ha evaluado el rechazo de los médicos a prescribir insulina a sus
pacientes; el retraso en intensificar el tratamiento impide una atención adecuada y de …